KRAS mutations and rectal cancer response to chemoradiation: are we closer to personalization of therapy?
about
KRAS Mutation Status Is Not a Predictor for Tumor Response and Survival in Rectal Cancer Patients Who Received Preoperative Radiotherapy With 5-Fluoropyrimidine Followed by Curative Surgery.Germline and somatic genetic predictors of pathological response in neoadjuvant settings of rectal and esophageal cancers: systematic review and meta-analysis.Role of KRAS mutation as predictor of pathologic response after neoadjuvant chemoradiation therapy for rectal cancer.
P2860
KRAS mutations and rectal cancer response to chemoradiation: are we closer to personalization of therapy?
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
KRAS mutations and rectal canc ...... to personalization of therapy?
@en
KRAS mutations and rectal canc ...... to personalization of therapy?
@nl
type
label
KRAS mutations and rectal canc ...... to personalization of therapy?
@en
KRAS mutations and rectal canc ...... to personalization of therapy?
@nl
prefLabel
KRAS mutations and rectal canc ...... to personalization of therapy?
@en
KRAS mutations and rectal canc ...... to personalization of therapy?
@nl
P2860
P1476
KRAS mutations and rectal canc ...... to personalization of therapy?
@en
P2093
George J Chang
Sunil Krishnan
P2860
P2888
P304
P356
10.1245/S10434-013-3107-2
P577
2013-07-18T00:00:00Z
P5875
P6179
1014720262